Complex Decisions and Real World Evidence (RWE)

Healthcare professionals decide on the best therapies for their patients diagnosed with MS. They also determine in which moment and in which combination different treatments will offer the highest benefit.

However, clinical research doesn’t always answer the questions of healthcare professionals and decision-makers about standards of care or reimbursement of therapies.

The HTx project will test methods to combine all the data available from clinical research and real-world medical practice into artificial intelligence (AI) models, assessing therapeutic pathways on a personalised basis.

Such an AI-powered web application will allow healthcare professionals to identify the best therapeutic pathway for people with MS, based on their characteristics, in real-time, discussed with them during a consultation. This will also prove useful for health authorities that decide on the reimbursement of certain therapies. This tool is meant to assess the combination of MS treatments, that are most probable to prevent relapses for a person living with MS, based on personal characteristics.

Shared Decision Making in Health Technology Assessment

On 29 November 2022 we ensured meaningful patient involvement at the HTx workshop held under the title of “Shared Decision Making”. The objective of the event was to compile ways in which clinicians and patients can use Real-World Evidence (RWE) to explore expectations regarding the outcome(s) of treatment and to make shared decisions.